American association of clinical endocrinologists and American college of endocrinology position statement on the association of testosterone and cardiovascular risk

Endocrine Practice

Volumn 21, Issue 9, 2015, Pages 1066-1073

  Goodman, Neil ^a   Guay, Andre ^b   Dandona, Paresh ^c   Dhindsa, Sandeep ^d   Faiman, Charles ^e   Cunningham, Glenn R ^f  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUTEINIZING HORMONE; TESTOSTERONE;

ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAM; HUMAN; HYPERTENSION; HYPOGONADISM; INSULIN RESISTANCE; KIDNEY FAILURE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVASCULARIZATION; WAIST CIRCUMFERENCE; ADVERSE EFFECTS; AGED; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMPLICATION; CONSENSUS; DEFICIENCY; DRUG LABELING; ENDOCRINOLOGY; FOOD AND DRUG ADMINISTRATION; HORMONE SUBSTITUTION; MALE; MEDICAL SOCIETY; MIDDLE AGED; RISK FACTOR; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CONSENSUS; DRUG LABELING; ENDOCRINOLOGY; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; RISK FACTORS; SOCIETIES, MEDICAL; TESTOSTERONE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84982166382     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP14434.PS     Document Type: Article

References (51)

1. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.
2. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e85805.
3. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93:68-75.
4. Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab. 2009;94:2482-2488.
5. Haider A, Yassin A, Doros G, Saad F. Effects of longterm testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol. 2014;2014:683515.
6. Baillargeon J, Urban RJ, Kuo YF, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48:1138-1144.
7. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
8. Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009;12:5-12.
9. Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract. 2002;8:440-456.
10. Dandona P, Dhindsa S. Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab. 2011;96:2643-2651.
11. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96:2341-2353.
12. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-Aged men. Diabetes Care. 2004;27:1036-1041.
13. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-Analysis. JAMA. 2006;295: 1288-1299.
14. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116:2694-2701.
15. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a metaanalytic study. Eur J Endocrinol. 2011;165:687-701.
16. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166:1660-1665.
17. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-Analysis. J Clin Endocrinol Metab. 2011;96:3007-3019.
18. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34:828-837.
19. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73:602-612.
20. Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-Aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7:3495-3503.
21. Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol. 2014;2014:527470.
22. Grossmann M, Hoermann R, Wittert G, Yeap BB. Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-Analysis of randomized controlled clinical trials. Clin Endocrinol (Oxf). 2014 Dec 29 [Epub ahead of print].
23. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-Analysis. J Clin Endocrinol Metab. 2010;95:2560-2575.
24. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
25. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediatefrail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010; 95:639-650.
26. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355:1647-1659.
27. Borst SE, Yarrow JF, Conover CF, et al. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab. 2014;306:E433-E442.
28. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89:503-510.
29. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab.1999;84:2647-2653.
30. Gianatti EJ, Dupuis P, Hoermann R, et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014;37:2098-2107.
31. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-Aged and older men: a meta-Analysis of randomized, placebocontrolled trials. J Gerontol A Biol Sci Med Sci. 2005;60: 1451-1457.
32. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-Analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29-39.
33. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-Analysis of placebocontrolled randomized trials. BMC Med. 2013;11:108.
34. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-Analysis. Expert Opin Drug Saf. 2014;13:1327-1351.
35. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050-2058.
36. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169:725-733.
37. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015;90:224-251.
38. Morgentaler A, Traish A, Kacker R. Deaths and cardiovascular events in men receiving testosterone. JAMA. 2014;311:961-962.
39. Traish AM, Guay AT, Morgentaler A. Death by testosterone? We think not! J Sex Med. 2014;11:624-629.
40. Dhindsa S, Batra M, Dandona P. Deaths and cardiovascular events in men receiving testosterone. JAMA. 2014;311:964.
41. Jones TH, Channer KS. Deaths and cardiovascular events in men receiving testosterone. JAMA. 2014;311:962-963.
42. Morgentaler A, Lunenfeld B. Testosterone and cardiovascular risk: world's experts take unprecedented action to correct misinformation. Aging Male. 2014;17:63-65.
43. U.S. Food and Drug Administration. Testosterone products: drug safety communication-FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm436280.htm. Accessed March 4, 2015.
44. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173: 1465-1466.
45. Garnick MB. Testosterone replacement therapy faces FDA scrutiny. JAMA. 2015;313:563-564.
46. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96:2430-2439.
47. Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab. 2007;92:549-555.
48. Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010;33:1186-1192.
49. Chandel A, Dhindsa S, Topiwala S, Chaudhuri A, Dandona P. Testosterone concentration in young patients with diabetes. Diabetes Care. 2008;31:2013-2017.
50. Mogri M, Dhindsa S, Quattrin T, Ghanim H, Dandona P. Testosterone concentrations in young pubertal and postpubertal obese males. Clin Endocrinol (Oxf). 2013;78: 593-599.
51. U.S. Food and Drug Administration. Testosterone products: FDA/CDER statement-risk of venous blood clots. Available at: http://www.fda.gov/safety/medwatch/safe tyinformation/safetyalertsforhumanmedicalproducts/ucm402054.htm.